Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 3/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | PRKACA | P17612 | 1/20 | 0.39 |
| ▸ | PRKACG | P22612 | 1/20 | 0.39 |
| ▸ | PRKACB | P22694 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 2/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.38 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.36 |
| ▸ | BCDIN3D | Q7Z5W3 | 1/20 | 0.35 |
| ▸ | TACR1 | P25103 | 2/20 | 0.35 |
| ▸ | WNT3A | P56704 | 1/20 | 0.35 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17524747 | 1.00 | HTR2C (0.45) | HTR2CL3MBTL1PRKACAPRKACGPRKACB | |
| Hydrochloric Acid SCHEMBL29236437 | 0.98 | HTR2C (0.46) | HTR2CL3MBTL1PRKACAPRKACGPRKACB | |
| Hydrochloric Acid SCHEMBL29236436 | 0.98 | HTR2C (0.46) | HTR2CL3MBTL1PRKACAPRKACGPRKACB | |
| SCHEMBL24540994 | 0.90 | HTR2C (0.42) | HTR2CL3MBTL1KDM1APARP1PARP2 | |
| SCHEMBL30859503 | 0.90 | HTR2C (0.40) | HTR2CL3MBTL1PRKACAPRKACGPRKACB | |
| SCHEMBL24541088 | 0.87 | PRKACA (0.37) | HTR2CL3MBTL1PRKACAPRKACGPRKACB | |
| SCHEMBL26084665 | 0.81 | HTR1A (0.51) | HTR2CPRKACAPRKACGPRKACBKDM1A | |
| SCHEMBL26084666 | 0.81 | HTR1A (0.51) | HTR2CPRKACAPRKACGPRKACBKDM1A | |
| SCHEMBL8321907 | 0.81 | CSNK1D (0.43) | PRKACAPRKACGPRKACBKDM1ATACR1 | |
| SCHEMBL280628 | 0.81 | CSNK1D (0.43) | PRKACAPRKACGPRKACBKDM1ATACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4732837-A2 | NOVEL PRMT5 INHIBITORS | Amgen Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| EP-4263545-B1 | PRMT5 INHIBITORS | AMGEN INC (US) | 2026-04-01 | — | — | EP | disclosed |
| US-20250388585-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-12448388-B2 | PRMT5 inhibitors and uses thereof | GILEAD SCIENCES, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| WO-2025098450-A1 | PRMT5 INHIBITOR AND PREPARATION METHOD THEREFOR | 北京泰德制药股份有限公司 | 2025-05-15 | — | — | WO | disclosed |
| CN-119968371-A | Novel PRMT5 inhibitor and application thereof | 上海湃隆生物科技有限公司 | 2025-05-09 | — | — | CN | disclosed |
| CN-119859155-A | Tri-fused ring derivative inhibitor, preparation method and application thereof | 江苏豪森药业集团有限公司 | 2025-04-22 | — | — | CN | disclosed |
| WO-2025077856-A1 | TRICYCLIC-CARBONYL-NITROGEN HETEROCYCLIC DERIVATIVES AND USE THEREOF | Beijing Double-Crane Runchuang Technology Co., Ltd. (CN) | 2025-04-17 | — | — | WO | disclosed |
| CN-119823149-A | Tricyclic derivative inhibitor, preparation method and application thereof | 江苏豪森药业集团有限公司 | 2025-04-15 | — | — | CN | disclosed |
| CN-119731162-A | PRMT5 inhibitors | 北京望实智慧科技有限公司 | 2025-03-28 | — | — | CN | disclosed |
| WO-2021198956-A1 | COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS | NUEVOLUTION A/S (DK) | 2021-10-07 | — | — | WO | disclosed |
| WO-2021198955-A1 | COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS | NUEVOLUTION A/S (DK) | 2021-10-07 | — | — | WO | disclosed |
| WO-2021198955-A1 | COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS | NUEVOLUTION A/S (DK) | 2021-10-07 | — | — | WO | disclosed |
| EP-3177611-B1 | OPTIONALLY FUSED HETEROCYCLYL-SUBSTITUTED DERIVATIVES OF PYRIMIDINE USEFUL FOR THE TREATMENT OF INFLAMMATORY, METABOLIC, ONCOLOGIC AND AUTOIMMUNE DISEASES | NUEVOLUTION AS (DK) | 2021-10-06 | — | — | EP | disclosed |
| US-10689383-B2 | Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases | NUEVOLUTION A/S (DK) | 2020-06-23 | — | — | US | disclosed |
| US-20190209995-A1 | Apparatus and Process for the Automated Chemical Synthesis of Compounds | ETH ZURICH (CH) | 2019-07-11 | — | — | US | disclosed |
| WO-2018116285-A1 | SUBSTITUTED MORPHOLINE DERIVATIVES AS ROR GAMMA MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2018-06-28 | — | — | WO | disclosed |
| US-20170327503-A1 | OPTIONALLY FUSED HETEROCYCLYL-SUBSTITUTED DERIVATIVES OF PYRIMIDINE USEFUL FOR THE TREATMENT OF INFLAMMATORY, METABOLIC, ONCOLOGIC AND AUTOIMMUNE DISEASES | NUEVOLUTION A/S (DK) | 2017-11-16 | — | — | US | disclosed |
| US-20170327503-A1 | OPTIONALLY FUSED HETEROCYCLYL-SUBSTITUTED DERIVATIVES OF PYRIMIDINE USEFUL FOR THE TREATMENT OF INFLAMMATORY, METABOLIC, ONCOLOGIC AND AUTOIMMUNE DISEASES | NUEVOLUTION A/S (DK) | 2017-11-16 | — | — | US | disclosed |
| WO-2016020295-A1 | OPTIONALLY FUSED HETEROCYCLYL-SUBSTITUTED DERIVATIVES OF PYRIMIDINE USEFUL FOR THE TREATMENT OF INFLAMMATORY, METABOLIC, ONCOLOGIC AND AUTOIMMUNE DISEASES | NUEVOLUTION A/S (DK) | 2016-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388585-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT1, PRMT5, PRMT6 | HTR2C 4179/4885L3MBTL1 88/4885PRKACA 460/4885 |
| US-20190209995-A1 | Apparatus and Process for the Automated Chemical Synthesis of Compounds | SQLE, FAH, ACACB | HTR2C 1579/4885L3MBTL1 4762/4885PRKACA 1609/4885 |
| US-10689383-B2 | Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases | RORA, RORC, RORB | HTR2C 4139/4885L3MBTL1 4748/4885PRKACA 1305/4885 |
| US-12448388-B2 | PRMT5 inhibitors and uses thereof | PRMT5, PRMT1, PRMT9 | HTR2C 4597/4885L3MBTL1 284/4885PRKACA 492/4885 |
| US-20170327503-A1 | OPTIONALLY FUSED HETEROCYCLYL-SUBSTITUTED DERIVATIVES OF PYRIMIDINE USEFUL FOR THE TREATMENT OF INFLAMMATORY, METABOLIC, ONCOLOGIC AND AUTOIMMUNE DISEASES | PPARD, PPARG, RORC | HTR2C 3076/4885L3MBTL1 4725/4885PRKACA 1357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.